宜明昂科-B(01541)收到AXION BIO的授权及合作协议项下里程碑付款

智通财经
Jul 30, 2025

智通财经APP讯,宜明昂科-B(01541)发布公告,于IMM2510/ AXN-2510获FDA批准于美国展开I期临床试验后,公司已从Instil收取1000万美元的里程碑付款。截至本公告日期,根据授权及合作协议收取的付款总额已达3000万美元(包括里程碑付款),显示公司与Instil之间的持续进展及坚定承诺。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10